S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.28
+1.60
+9.59%
AVTX · Avalo Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Avalo Therapeutics Inc (AVTX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$12.27
-0.08
(-0.65%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$12.27
$12.22
$13.13
52-WEEK RANGE
$12.27
$11.21
$24.27
What's happening
- AVTX is down 0.65% today, trading at $12.27. — Live quote
- Volume today (52,917) is well below its 3-month average of 1,217,490. (Finnhub fundamentals)
- Reports earnings on 2026-11-04, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.83 actual vs. $-0.59 estimated (-39.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 10
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (20 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AVTX
-31.94%
vs S&P 500
-44.72%
1-YEAR RETURN
AVTX
-27.61%
vs S&P 500
-42.17%
6-MONTH RETURN
AVTX
-14.29%
3-MONTH RETURN
AVTX
-34.33%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.83
Est. $-0.59
MISS -39.8%
2026-04-26 (Q1 2026)
$-0.98
Est. $-1.05
BEAT +6.3%
2026-01-26 (Q4 2025)
$-1.13
Est. $-1.49
BEAT +24.3%
2025-10-26 (Q3 2025)
$-2.19
Est. $-1.69
MISS -29.4%
Valuation Measures & Ratios
Enterprise Value4$589.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)11398.65
Price / Book72.17
EV4 / Revenue9985.39
EV4 / EBITDA—
Profit Margin-23254.24%
Operating Margin-33461.02%
Return on Equity (ROE8)-58.03%
Return on Assets (ROA9)-48.22%
Avg Volume (3M)1,217,490
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $809.5M | $300.9M | $178.2M | $53.1M | $83.7M |
| P/E | -7.54 | -3.57 | -4.29 | 0.61 | -6.47 |
| Price/Book | 1.80 | 4.40 | 1.95 | 0.51 | 0.68 |
| EV/EBITDA | -7.98 | -3.74 | -2.30 | — | — |
| ROE | -23.93% | -123.20% | -45.33% | 83.76% | -10.55% |
| ROA | -21.88% | -84.27% | -33.18% | 69.19% | -9.34% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,405,304
Change from Prior Settlement-11.76%
% of Float—
Days to Cover (Short Ratio)8.80
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -69.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -23254.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -27.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AVTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | — | — | $249.0K | $0 | $0 |
| Operating income | -$31.5M | -$20.9M | -$19.2M | -$19.3M | -$14.7M | -$12.9M | -$9.6M | -$32.8M |
| Net income | -$36.4M | -$19.6M | -$30.6M | -$20.8M | -$13.1M | $23.0M | $98.5M | -$121.3M |
| EPS (diluted) | $-0.83 | $-0.98 | $-2.19 | $-1.92 | $-1.25 | $-2.83 | $-14.07 | $-141.14 |
| EPS (basic) | $-0.83 | $-0.98 | $-2.19 | $-1.92 | $-1.25 | $0.98 | $4.21 | $-141.14 |
| Operating margin | — | — | — | — | — | -$5.2K | — | — |
| Net margin | — | — | — | — | — | $9.3K | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $490.8M | $99.9M | $116.5M | $125.1M | $126.6M | $138.5M | $150.7M | $98.5M |
| Total liabilities | $42.1M | $31.6M | $33.4M | $33.6M | $22.0M | $15.9M | $17.7M | $75.7M |
| Stockholders' equity | $448.7M | $68.3M | $83.0M | $91.5M | $104.6M | $122.6M | $133.0M | $21.1M |
| Total current assets | $407.9M | $88.8M | $105.3M | $113.8M | $115.2M | $126.9M | $138.9M | $86.1M |
| Total current liabilities | $21.1M | $11.6M | $12.9M | $8.0M | $9.3M | $5.6M | $7.0M | $60.7M |
| Cash & equivalents | $85.4M | $25.0M | $15.9M | $27.0M | $42.3M | $125.0M | $134.5M | $81.9M |
| Marketable securities (current) | $314.9M | $57.0M | $82.5M | $84.7M | $71.0M | — | $0 | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $71.9M | — | $0 | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.3M | $356.0K | $137.0K | $474.0K | $2.4M | $681.0K | $283.0K | $1.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $0 | $0 | $35.0K | $117.0K | $197.0K | $275.0K | $350.0K | $1.1M |
| Common stock & paid-in capital | $53.0K | $25.0K | $18.0K | $18.0K | $11.0K | $11.0K | $10.0K | $10.0K |
| Retained earnings | -$504.5M | -$468.2M | -$448.5M | -$434.8M | -$404.2M | -$383.4M | -$370.3M | -$334.9M |
| Accumulated other comprehensive income (loss) | -$583.0K | -$6.0K | $68.0K | $41.0K | -$34.0K | — | $0 | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.0M | -$17.7M | -$14.2M | -$16.4M | -$11.4M | -$9.5M | -$15.0M | -$11.5M |
| Investing cash flow | -$329.9M | $25.5M | $2.4M | -$13.3M | -$70.9M | $0 | $0 | $0 |
| Financing cash flow | $410.2M | $1.4M | $687.0K | $14.4M | -$469.0K | $0 | $67.7M | $0 |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $17.0K | $17.0K | $16.0K | $59.0K | $134.0K | $135.0K | $68.0K | $34.0K |
| Share-based compensation | $5.3M | $3.6M | $4.5M | $3.2M | $2.7M | $3.2M | $2.9M | $1.8M |
| Deferred income taxes | $17.0K | $12.0K | $131.0K | $10.0K | $16.0K | $8.0K | $114.0K | -$14.0K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | $0 | $0 |
| Change in accounts payable | $3.0M | $219.0K | -$337.0K | -$1.9M | $1.7M | $398.0K | -$1.5M | $1.2M |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $779.0K | $0 | $1.0K | $509.0K | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $59.0K | $441.0K | $1.9M | $18.1M | $5.4M |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M |
| EPS (diluted) | $-5.84 | $-20.91 | $-113.58 | $-1063.00 | — |
| EPS (basic) | $-5.84 | $-7.94 | $-113.58 | $-1063.00 | — |
| Operating margin | -$123.6K | -$15.5K | -$1.4K | -$207 | -$1.5K |
| Net margin | -$132.6K | -$8.0K | -$1.6K | -$231 | -$1.6K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
| Stockholders' equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M |
| Total current assets | $105.3M | $138.9M | $8.4M | $16.4M | $61.8M |
| Total current liabilities | $12.9M | $7.0M | $4.6M | $22.1M | $19.9M |
| Cash & equivalents | $15.9M | $134.5M | $7.4M | $13.2M | $54.6M |
| Marketable securities (current) | $82.5M | $0 | — | — | — |
| Inventory | — | — | $0 | $20.0K | $38.0K |
| Property, plant & equipment | — | — | — | — | — |
| Goodwill | $10.5M | $10.5M | $10.5M | $14.4M | $14.4M |
| Intangible assets | — | — | — | $0 | $38.0K |
| Accounts payable | $137.0K | $283.0K | $446.0K | $2.9M | $3.4M |
| Deferred revenue (current) | — | — | $0 | $88.0K | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $35.0K | $350.0K | $1.4M | $1.7M | $2.3M |
| Common stock & paid-in capital | $18.0K | $10.0K | $1.0K | $0 | $9.0K |
| Retained earnings | -$448.5M | -$370.3M | -$335.1M | -$303.8M | -$262.2M |
| Accumulated other comprehensive income (loss) | $68.0K | $0 | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Investing cash flow | -$81.7M | $356.0K | -$133.0K | -$95.0K | -$113.0K |
| Financing cash flow | $14.6M | $175.8M | $25.0M | -$14.7M | $106.8M |
| Free cash flow | — | — | — | -$26.8M | -$71.0M |
| Capital expenditures | — | — | — | $95.0K | $113.0K |
| Depreciation & amortization | $344.0K | $169.0K | $158.0K | $166.0K | $1.7M |
| Share-based compensation | $13.6M | $5.9M | $3.5M | $7.6M | $8.2M |
| Deferred income taxes | $165.0K | $114.0K | $14.0K | $28.0K | $22.0K |
| Change in accounts receivable | — | — | $0 | -$1.1M | -$1.1M |
| Change in inventory | — | $0 | -$20.0K | -$18.0K | $35.0K |
| Change in accounts payable | -$146.0K | -$163.0K | -$2.4M | -$487.0K | $796.0K |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $510.0K | $0 | — | — | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AVTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-10 to 2026-09-16
Recent transactions
- Insiders have net sold 107,421 shares over the last 182 days, across 0 purchases and 12 sales.
- Most recent: Sullivan Christopher Ryan (Chief Financial Officer) — Option exercise of 12,394 shares on 2026-09-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)107,421 sh(12 txns)
Net Shares-107,421
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 2026-09-16 | 12,394 |
| Doyle Mittie | Chief Medical Officer | Option exercise | 2026-08-28 | 679 |
| Riley Jennifer | Chief Strategy Officer | Open market sale | 2026-08-11 | 2,655 |
| VARKI PAUL | Chief Legal Officer | Tax withholding | 2026-06-10 | 1,081 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 12,394 | $9.88 |
| 2026-09-16 | Sullivan Christopher Ryan | Chief Financial Officer | Open market sale | 12,394 | $16.33 |
| 2026-09-10 | Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 10,185 | $8.04 |
| 2026-09-10 | Sullivan Christopher Ryan | Chief Financial Officer | Open market sale | 10,185 | $17.62 |
| 2026-08-28 | Doyle Mittie | Chief Medical Officer | Option exercise | 679 | $8.04 |
| 2026-08-28 | Doyle Mittie | Chief Medical Officer | Open market sale | 679 | $20.00 |
| 2026-08-18 | Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 31,031 | $9.88 |
| 2026-08-18 | Sullivan Christopher Ryan | Chief Financial Officer | Open market sale | 31,031 | $20.05 |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 37,945 | $9.88 |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Option exercise | 2,876 | $9.88 |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Open market sale | 37,945 | $19.85 |
| 2026-08-17 | Sullivan Christopher Ryan | Chief Financial Officer | Open market sale | 3,749 | $19.94 |
| 2026-08-17 | Doyle Mittie | Chief Medical Officer | Option exercise | 1,000 | $12.65 |
| 2026-08-17 | Doyle Mittie | Chief Medical Officer | Open market sale | 1,000 | $20.00 |
| 2026-08-11 | Riley Jennifer | Chief Strategy Officer | Open market sale | 2,655 | $19.59 |
| 2026-08-10 | Doyle Mittie | Chief Medical Officer | Option exercise | 679 | $8.04 |
| 2026-08-10 | Doyle Mittie | Chief Medical Officer | Open market sale | 679 | $20.00 |
| 2026-07-27 | Doyle Mittie | Chief Medical Officer | Option exercise | 1,000 | $12.65 |
| 2026-07-27 | Doyle Mittie | Chief Medical Officer | Open market sale | 1,000 | $20.00 |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Option exercise | 2,875 | $12.65 |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Option exercise | 1,779 | $8.04 |
| 2026-06-30 | Doyle Mittie | Chief Medical Officer | Open market sale | 4,654 | $20.00 |
| 2026-06-23 | Doyle Mittie | Chief Medical Officer | Option exercise | 1,450 | $8.04 |
| 2026-06-23 | Doyle Mittie | Chief Medical Officer | Open market sale | 1,450 | $18.00 |
| 2026-06-10 | Riley Jennifer | Chief Strategy Officer | Tax withholding | 588 | $13.10 |
| 2026-06-10 | VARKI PAUL | Chief Legal Officer | Tax withholding | 1,081 | $13.10 |
| 2026-06-10 | Sullivan Christopher Ryan | Chief Financial Officer | Tax withholding | 138 | $13.10 |
| 2026-06-10 | Doyle Mittie | Chief Medical Officer | Tax withholding | 1,084 | $13.10 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:31 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-28 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
Recent news
Headlines about AVTX (Avalo Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
AVTX Nov 2026 35.000 call (AVTX261120C00035000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
(AVTX) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-17 -
H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy
Investing.com · 2026-10-16 -
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $30
Moomoo · 2026-10-16 -
AVTX Oct 2026 20.000 put (AVTX261016P00020000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-15 -
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · 2026-09-29 -
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Yahoo Finance · 2026-09-23 -
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise
Seeking Alpha · 2026-09-04
No headlines in this category right now — try “All”.